Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data

Abstract We compared the cost-effectiveness of gemcitabine plus nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX)—standard first-line treatments for metastatic pancreatic cancer in Japan. This retrospective cohort study included patients with metastatic pancreatic cancer treated at the National Ca...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Akira Shinohara, Yuki Takumoto, Junko Tauchi, Koki Morishita, Toshikatsu Kawasaki, Manabu Akazawa
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2025-01-01
Edice:	Scientific Reports
Témata:	Gemcitabine plus nab-paclitaxel Modified FOLFIRINOX Pancreatic cancer Chemotherapy Cost-effectiveness
On-line přístup:	https://doi.org/10.1038/s41598-024-80549-1
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!